The extent to which medical and surgical procedures may potentially employ emerging fibrin (and other) sealants, glues, hemostats, wound closure and anti-adhesion products is driven by the utility offered by these products in specific clinical applications, which may be grouped by the following consideration:
| Category I: Important and Enabling | Important to prevent excessive bleeding and transfusion, to ensure safe procedure, and to avoid mortality and to avoid complications associated with excessive bleeding and loss of blood. |
| Category II: Improved Clinical Outcome | Reduces morbidity due to improved procedure, reduced surgery time, and prevention of complications such as fibrosis, post-surgical adhesion formation, and infection (includes adjunct to minimally invasive surgery). |
| Category III: Cost-Effective and Time-Saving | Immediate reduction in surgical treatment time and follow-up treatments. |
| Category IV: Aesthetic and Perceived Benefits | Selection is driven by aesthetic and perceived benefits, resulting in one product being favored over a number of medically equivalent treatments. |
Source: MedMarket Diligence, LLC; Report #S190.
MedMarket Diligence has assessed the procedure volumes, worldwide, that fall into these categories based on the utility offered by adjunctive surgical sealant and glues products for each of the major clinical categories:
Source: MedMarket Diligence, LLC; Report #S190.
If you enjoyed this article, please consider sharing it!
